Pharmaceutical company Lotus Tissue Repair has secured $26 million in Series A venture funding. The financing round was led by Third Rock Ventures.
The firm intends to use the proceeds to enhance its proprietary recombinant collagen type VII (rC7) technology. Lotus’ board of directors includes Neil Exter, a partner at Third Rock Ventures, and Philip Reilly, venture partner at Third Rock Ventures.
Click here for the release from Lotus Tissue Repair.